Physicians' Academy for Cardiovascular Education

Preventing CVD in Patients with T2DM: How to apply novel outcome data with GLP-1 RA to clinical practice

Meeting report with video, highlights and slides of PACE-CME symposium held at EuroPrevent 2018 in Ljubljana. More to be added soon

Meeting Impression | Preventing CVD in Patients with T2DM

May 3, 2018 - Ljubljana, Slovenia
May 3, 2018 - Ljubljana, Slovenia

Download the meeting impression of this PACE symposium during EuroPrevent 2018, that considered how to apply novel outcome data with GLP-1 RA to clinical practice.

Summary | Practical management of cardiovascular risk: Lessons from latest diabetes trials

May 3, 2018 – Prof. Lars Rydén, MD

This is a summary of the presentation by prof. Rydén, in which he reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

Summary | Diabetes: How to reduce risk from a cardiovascular perspective?

May 3, 2018 – Prof. Diederick Grobbee, MD

This is a summary of presentation given by prof. Grobbee, in which he discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and the effect of newer agents.

Summary | The cardiovascular challenge for primary care in diabetes

May 3, 2018 – Prof. Richard Hobbs, MD

This summary of the presentation by prof. Hobbs illustrates why diabetes poses a high burden to primary health care, since patients with T2DM are at high CV risk. This risk can be lowered by targeting various risk factors.

Slides: Practical management of cardiovascular risk: Lessons from latest diabetes trials

Presentation Prof. Lars Ryden

Slides (presentation) - June 25, 2018 - Prof. Lars Ryden - PACE-CME symposium at EuroPrevent 2018

Slides as educational service to PACE members and meeting participants

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden - Online CME
Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

Slides: Diabetes: How to reduce risk from a cardiovascular perspective?

Presentation Prof. Rick Grobbee

Slides (presentation) - June 25, 2018 - Prof. Rick Grobbee

This lecture by prof Richard Hobbs was part of a CME accredited symposium: 'Preventing CVD in Patients with T2DM How to apply novel outcome data with GLP-1 RA to clinical practice?' held at EuroPrevent 2018 in Ljubljana

Slides: The cardiovascular challenge for primary care in diabetes

Presentation Prof. Richard Hobbs

Slides (presentation) - June 25, 2018 - EuroPrevent 2018, Ljubljana - Prof. Richard Hobbs - CME symposium at EuroPrevent 2018
This lecture by prof Richard Hobbs was part of a CME accredited symposium: 'Preventing CVD in Patients with T2DM How to apply novel outcome data with GLP-1 RA to clinical practice?' held at EuroPrevent 2018 in Ljubljana

Slides as educational service to PACE members and meeting participants

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - June 25, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands
Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and additional effects observed in recent outcome trials of newer agents.

Prof. Grobbee discusses how to reduce CV risk in patients with T2DM, considering the effects of glucose control and additional effects observed in recent outcome trials of newer agents.

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME
Prof. Hobbs stresses  the importance of CVRM in primary care and how to manage this risk beyond glucose control.

Prof. Hobbs stresses the importance of CVRM in primary care and how to manage this risk beyond glucose control.

Preventing CVD in Patients with T2DM: How to apply novel outcome data with GLP-1 RA to clinical practice
Preventing CVD in Patients with T2DM: How to apply novel outcome data with GLP-1 RA to clinical practice